Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in pancreatic cancer
- Trial result
Pancreatic cancer
HCQ (autophagy inhibitor) + CPC (AKT/EMT-modulating repurposed agent) added to mFOLFIRINOX delivers 39% ORR in 1L advanced PDAC
Hydroxychloroquine (HCQ), a lysosomotropic autophagy inhibitor, and chlorphenesin carbamate (CPC), a repurposed agent proposed to blunt AKT-mediated EMT, were combined with first-line modified FOLFIRINOX in a…
NCT05083780 - New trial Spotlight
Pancreatic cancer
Phase 2 VS-7375 oral KRAS G12D (ON/OFF) inhibitor ± EGFR antibody cetuximab in metastatic PDAC.
Verastem, Inc. is running TARGET-D 201 (NCT07644559), an open-label, multicenter Phase 2 study testing VS-7375—an oral, KRAS G12D–selective “ON/OFF” small-molecule inhibitor—given as monotherapy and in combination…
NCT07644559 Exploratory - New trial
Pancreatic cancer
Phase 1b samuraciclib trial tests CDK7 inhibitor transcription/cell-cycle blockade in basal PDAC
This single-institution, single-arm, open-label Phase 1b window-of-opportunity study evaluates whether samuraciclib (CT7001)—an oral small-molecule CDK7 inhibitor that disrupts transcriptional CDK activity and…
NCT07645651 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D-selective RAS(ON) inhibitor plus chemo in 1L metastatic PDAC.
This registrational, randomized, double-blind, placebo-controlled Phase 3 study (RASolute 305) tests whether adding zoldonrasib (RMC-9805)—Revolution Medicines’ oral KRAS G12D-selective “RAS(ON)” inhibitor that…
NCT07621718 Registrational - New trial
Pancreatic cancer
Early-feasibility Aliya PEF system irreversible electroporation (non-thermal membrane disruption) in pancreatic tumors.
This early feasibility, single-arm interventional study at The Ohio State University Comprehensive Cancer Center evaluates whether endoscopic ultrasound (EUS)-guided pulsed electric field (PEF) ablation can be…
NCT07619417 Exploratory - New trial
Pancreatic cancer
Phase 1/1b AB801 AXL receptor tyrosine kinase inhibitor with chemo + PD-(L)1 blockade
This Phase 1/1b, open-label, multi-cohort study evaluates AB801—an oral small-molecule AXL receptor tyrosine kinase inhibitor from Arcus Biosciences—combined with standard chemotherapy and immune checkpoint blockade…
NCT07619313 Exploratory - New trial
Pancreatic cancer
Phase 1 64Cu-DOTA-A2DM PET: PSCA-targeted immunoPET tracer (anti-PSCA scFv-Fc2)
This Phase 1 City of Hope study evaluates whether 64Cu-DOTA-A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) can safely and feasibly generate high-quality PET images in locally advanced or metastatic, unresectable PSCA-expressing…
NCT07608627 Exploratory - New trial
Pancreatic cancer
Phase 1 MT-601 multiTAA-specific adoptive T cells target multiple shared tumor antigens.
Marker Therapeutics’ PANACEA Phase 1 dose-escalation with expansion tests MT-601, an autologous (patient-derived) multi–tumor-associated antigen (multiTAA)–specific T-cell product designed to recognize several shared…
NCT06549751 Exploratory - New trial
Pancreatic cancer
N/A NanoKnife irreversible electroporation (cell-membrane nanopore ablation) in unresectable pancreatic cancer
Englewood Hospital and Medical Center is running this single-arm, prospective safety-and-outcomes study evaluating the NanoKnife Irreversible Electroporation (IRE) System used off-label to ablate unresectable…
NCT06937996 Exploratory - Trial result Spotlight
Pancreatic cancer
Daraxonrasib (RMC-6236) RAS(ON) multiselective inhibitor delivers 35% ORR in 2L RAS G12 PDAC
Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that binds GTP-bound mutant and wild-type RAS, evaluated in the Phase 1/2 RMC-6236-001 study (NCT05379985) in previously treated RAS-mutated PDAC.…
NCT05379985 - Trial result Spotlight
Pancreatic cancer
Intraperitoneal nivolumab (PD-1 blockade) yields 78% ascites control with minimal toxicity in GI/pancreaticobiliary cancers
Nivolumab (Opdivo), an anti–PD-1 immune checkpoint inhibitor, was administered intraperitoneally (IP) at 20 mg in 100 mL saline after paracentesis in a small, single-arm study of cytology-confirmed malignant ascites…
NCT05745233 - New trial Spotlight
Pancreatic cancer
Phase 3 atebimetinib MEK1/2 inhibitor plus modified GnP vs standard GnP in metastatic PDAC
Immuneering’s MAPKeeper 301 is a randomized, open-label Phase 3 trial testing whether adding atebimetinib—an oral small-molecule MEK1/MEK2 inhibitor targeting the MAPK pathway—to a modified schedule of gemcitabine +…
NCT07562152 Registrational - New trial
Pancreatic cancer
Phase 1b pitavastatin HMG‑CoA reductase inhibitor plus gemcitabine/nab‑paclitaxel in uPDAC.
This Phase 1b, open-label, randomized maintenance study at University of California, Irvine tests whether adding pitavastatin (a small‑molecule HMG‑CoA reductase inhibitor that suppresses the mevalonate/cholesterol…
NCT07549958 Exploratory - Trial result
Pancreatic cancer
Cadonilimab (AK104) PD-1/CTLA-4 bispecific + gem/nab-paclitaxel posts 33.9% ORR and 13.8-mo mOS in 1L advanced PDAC
Cadonilimab is a PD-1/CTLA-4 bispecific antibody (AK104) evaluated with gemcitabine + nab-paclitaxel (AG) in the Phase 2, multicenter, open-label COMPASSION-26 study (NCT05859750) as first-line therapy for…
NCT05859750 - New trial Spotlight
Pancreatic cancer
Phase 3 INCB161734 KRAS G12D–selective inhibitor plus chemo in metastatic PDAC
In this randomized, double-blind Phase 3 DAWN-303 trial from Incyte, patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) whose tumors harbor a KRAS G12D mutation are assigned to…
NCT07522073 Registrational - New trial
Pancreatic cancer
Phase II adaptive SBRT + defactinib (FAK) + avutometinib (RAF/MEK clamp) in advanced PDAC
Washington University and Verastem Oncology explore stromal and MAPK co-targeting wrapped around adaptive SBRT, with a safety lead-in. Unresectable PDAC still leans on FOLFIRINOX or gem/nab-paclitaxel with modest…
NCT07126158 Exploratory - Trial result Spotlight
Pancreatic cancer
Atorvastatin (HMG-CoA) + chemotherapy shows 70.3% tumor-marker declines in advanced PDAC
Atorvastatin, an HMG-CoA reductase inhibitor (statin), was paired with chemotherapy after a 260-line PDAC organoid biobank tied chemoresistance to cholesterol/glycosylation programs and showed statins could…
NCT06241352 - Trial result Spotlight
Pancreatic cancer
ELI-002 2P (mKRAS amphiphile) links strong T-cell response to longer RFS/OS in PDAC/CRC
ELI-002 2P is a lymph-node–targeted amphiphile vaccine (KRAS G12D/G12R peptides + CpG-7909) tested as monotherapy in MRD-positive patients after locoregional therapy in Phase 1 AMPLIFY-201 (n=25; PDAC=20, CRC=5). At…
- New trial Spotlight
Pancreatic cancer
Phase 1b Study of ASP2138, a CLDN18.2-directed CD3 Activator Bispecific mAb
Adults with resectable pancreatic ductal adenocarcinoma expressing CLDN18.2 receive neoadjuvant subcutaneous ASP2138 followed by investigator-selected adjuvant chemotherapy (mFOLFIRINOX, gemcitabine/nab-paclitaxel,…
NCT07024615 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 2/3 trial of BMS-986504, a selective PRMT5 inhibitor, in metastatic pancreatic cancer.
The study evaluates safety and efficacy of BMS-986504 when combined with gemcitabine and nab-paclitaxel versus standard chemo plus placebo in a randomized design. It enrolls treatment-naïve patients with metastatic…
NCT07076121 Registrational - New trial Spotlight
Pancreatic cancer
Phase 1 Trial of OMO-103, a Myc Inhibitor, in Pancreatic Cancer
This early Phase 1 trial is assessing OMO-103, a dominant-negative MYC inhibitor (Omomyc miniprotein) that disrupts MYC–MAX, in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.…
NCT07089940 Exploratory - New trial
Pancreatic cancer
Phase 2 NALIRIFOX trial with liposomal irinotecan (topoisomerase I inhibitor) in pancreatic cancer.
Medical University of South Carolina is conducting a single-center, open-label, randomized Phase 2 trial comparing NALIRIFOX versus modified gemcitabine, nab-paclitaxel plus cisplatin in previously untreated patients…
NCT07076212 Exploratory - New trial
Pancreatic cancer
Phase 2 mFOLFIRINOX Trial with Irinotecan Topoisomerase I Inhibition in Metastatic PDAC
This Phase 2 study by the University of Miami investigates whether ctDNA monitoring can guide early treatment changes in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma. Participants receive…
NCT07096362 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 1b Alpha DaRT diffusing alpha radiation emitter for pancreatic cancer
This Phase 1b multi-center study evaluates the safety and early efficacy of combining mFOLFIRINOX chemotherapy with Alpha DaRT—a device that emits targeted alpha particles—administered during the first four treatment…
NCT06698458 First-in-human - New trial
Pancreatic cancer
Phase 2: Acoustic Cluster Therapy (ultrasound-triggered microbubble enhancer) in pancreatic cancer.
This Phase 2 trial evaluates the safety and efficacy of combining Acoustic Cluster Therapy with modified FOLFIRINOX in patients with locally advanced, unresectable pancreatic cancer. Acoustic Cluster Therapy uses…
NCT06850623 Exploratory - New trial
Pancreatic cancer
Phase 1 Study of Suizenji Ultrasound-Guided HIFU Ablation for Unresectable Pancreatic Cancer
This open-label, non-randomized single-center study sponsored by SONIRE Therapeutics Inc. is evaluating the feasibility, safety, tolerability, and preliminary efficacy of Suizenji, an ultrasound-guided high-intensity…
NCT07033689 Exploratory - New trial Spotlight
Pancreatic cancer
Phase I/IIa Trial of E-EDV-D682 Nanocells Targeting EGFR in Metastatic PDAC
This randomized study compares the efficacy and safety of E-EDV-D682/GC nanocells in combination with gemcitabine (a ribonucleoside reductase inhibitor) and nab-paclitaxel (a tubulin inhibitor) versus standard…
NCT07049055 First-in-human - New trial
Pancreatic cancer
Phase 2 trial: Gemcitabine (ribonucleotide reductase inhibitor) and Nab-paclitaxel (tubulin inhibitor) alternating with mFOLFIRINOX
This study evaluates the safety and effectiveness of alternating Gemcitabine plus Nab-paclitaxel with mFOLFIRINOX as neoadjuvant treatment for borderline resectable pancreatic ductal adenocarcinoma. Patients must…
NCT07043270 Exploratory - New trial
Pancreatic cancer
Phase 1 Pilot: Paclitaxel (tubulin inhibitor) and NALIRIFOX in PDAC with peritoneal carcinomatosis
This trial by the University of Colorado, Denver evaluates safety and early efficacy of combining intraperitoneal paclitaxel with intravenous NALIRIFOX, a multi-agent chemotherapy regimen, in adults with pancreatic…
NCT07030283 Exploratory - New trial
Pancreatic cancer
Phase I trial of emavusertib IRAK4/FLT3 inhibitor with gemcitabine and nab-paclitaxel
This Phase I study evaluates the safety and optimal dosing of emavusertib combined with gemcitabine and nab-paclitaxel in patients with metastatic or unresectable pancreatic ductal adenocarcinoma. Sponsored by the…
NCT05685602
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.